Background: We describe an approach to estimating the cost-effectiveness of an intervention that changes health behaviour. The method captures the lifetime costs and benefits incurred by participants in an ongoing cluster-randomized controlled trial of an intervention that aims to change health behaviour. The existing literature only captures short-term economic and health outcomes.
Methods: We develop a state-transition Markov model of how individuals move between different health behaviour states over time. We simulate hypothetical data to describe the costs and health benefits of the intervention, illustrate how the data collected in the ongoing randomized controlled trial can be used and demonstrate how incremental cost-effectiveness ratios are estimated.
Results: On the basis of the simulated (i.e. hypothetical) data, we estimate the cost per quality-adjusted life year. The estimate reflects the lifetime health and economic consequences of the intervention.
Discussion: The method used for the cost-effectiveness analysis described in this paper is appropriate for investigating whether interventions that change health behaviour in relation to chronic diseases represent good value for money as compared to alternative uses of scarce healthcare resources.
Murray Cjl, Lopez ADQuantifying the burden of disease and injury attributable to ten major risk factors. In: Murray CJL, Lopez AD, eds. The global burden of disease: a comprehensive assessment of mor tality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Boston : Harvard School of Public Health on behalf of the World Health Organization and the World Bank, 1996, 295—325.
2.
Mokdad AH, Marks JS, Stroup DF, Gerberding JLActual causes of death in the United States. JAMA2000; 291: 1238—45.
3.
Drummond MF, Stoddart GL, Torrance GWMethods for the economic evaluation of health care programmes, 2nd edn. Oxford: Oxford University Press, 1997.
4.
Gold MR, Siegel JE, Russell LN, Weinstein MCCost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
5.
Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life . Health Economics1997; 6: 217—27.
6.
Briggs A., Schulpher M.An introduction to Markov modelling for economic evaluation. Pharmacoeconomics1998; 13: 397—409.
7.
Sonnenberg FA , Beck JRMarkov models in medical decision making: a practical guide. Med Decis Making1993; 13: 322—38.
8.
Clemen RTMaking hard decisions. An introduction to decision analysis. Pacific Grove: Duxbury Press, 1996 .
Stephenson J. , Bauman A., Armstrong T., Smith B., Bellew B.The costs of illness attributable to physical inactivity in Australia. A preliminary study. Canberra : Department of Health and Ageing, Australia, 2000.
11.
Brazier J., Usherwood T., Harper R., Thomas K.Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol1998; 51: 1115—28.
12.
Brazier J., Roberts J., Deverill M.The estimation of a preference-based measure of health from the SF-36. J Health Economics2002; 21: 271—92.
13.
Brazier J., Deverill M., Green C., Harper R., Booth A.A review of the use of health status measures in economic evaluation. Health Technol Assess1999; 3: 1—176.
14.
Drummond MF , Jefferson TOGuidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ1996 ; 313: 275—83.
15.
Herman WH, Hoerger TJ, Brandle M., et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med2005; 142: 381—3.
16.
Fiscella K., Franks P.Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counselling. JAMA1996; 275: 1247—52.
17.
Secker-Walker RH, Worden JK, Holland RR, Flynn BS, Detsky ASA mass media programme to prevent smoking among adolescents: costs and cost effectiveness. Tob Control1997; 6: 207—12.
18.
de Vries SO , Visser K., de Vries JA.Intermittent claudication: cost-effectiveness of revascularization versus exercise therapy. Radiology2002; 222: 25—36.
19.
Lowensteyn I., Coupal L., Zowall H., Grover SAThe cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease. J Cardiopulm Rehabil2000; 20: 147—55.
20.
Segal L., Dalton A., Richardson J.Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus. JHealth Promotion Int1998; 13: 197—210.
